AlphaSense and Evaluate

AlphaSense and Evaluate: Better Together

Effective pharmaceutical intelligence strategy requires more than access to forecasts and pipeline data — it requires the ability to interpret shifting market dynamics in real time. Staying ahead means understanding not only drug sales projections, competitive landscapes, and deal activity, but also what those projections mean for the market at large and how they may change based on evolving sentiment, new developments, and strategic repositioning.

Beyond having reliable commercial data, teams need context to answer critical questions, such as:

• What assumptions are embedded in this data?
• How are analysts and competitors reacting?
• Where are sentiment shifts signaling risk or upside?
• What developments could materially change the outlook?

This need for context is why many leading healthcare and pharmaceutical organizations choose to supplement a structured life sciences intelligence platform like Evaluate with an AI-powered market intelligence platform like AlphaSense.

Evaluate is built on robust, structured datasets, making it a trusted source for drug sales forecasts, consensus estimates, competitive benchmarking, epidemiology data, and deal tracking. The platform provides a quantitative foundation for portfolio planning, licensing decisions, and long-term commercial strategy. Teams use Evaluate to model opportunity size, compare assets, and understand how markets are projected to evolve.

However, structured forecasts alone cannot capture the full market picture. Evaluate focuses primarily on modeled data and curated datasets, but it misses the vast universe of unstructured content such as earnings transcripts, broker research, investor presentations, expert interviews, and real-time market commentary. It also does not provide advanced AI-driven search and generative capabilities designed to synthesize large volumes of qualitative information.

AlphaSense complements Evaluate by providing an added layer of real-time intelligence. Using AI-powered search and generative capabilities, AlphaSense enables teams to instantly surface emerging themes, sentiment shifts, competitive positioning changes, and regulatory signals across millions of documents. Instead of manually reviewing transcripts and research reports, users can ask complex, natural-language questions and receive synthesized answers grounded in primary source material in seconds.

Used together, the two platforms serve as a complete intelligence framework. Evaluate delivers the quantitative backbone — forecasts, pipeline visibility, and deal analytics — while AlphaSense provides the qualitative context that marries the narrative and the numbers.

For life sciences teams making high-stakes decisions in business development, portfolio strategy, commercial planning, or competitive intelligence, combining structured forecasting data with real-time market insight leads to faster, more informed, and more confident strategic decisions.

Below, we examine AlphaSense and Evaluate in more detail, highlighting key features, strengths, and limitations to demonstrate how the platforms work together to elevate healthcare and pharma market intelligence.

AlphaSense

Best for: Enhancing the value of life sciences databases through integration, AI capabilities, and additional external qualitative and quantitative sources that provide key context

AlphaSense is not a life sciences database, nor is it intended only for life sciences customers. Instead, it is an AI-driven market research platform that offers a centralized library of premium and proprietary content sets, extensive quantitative data, and AI capabilities for both real-time monitoring and historical research. AlphaSense is ideal for life sciences organizations that want to layer real-time qualitative insights and market context on top of traditional structured healthcare data to enable faster, more confident decision-making.

The benefit of incorporating AlphaSense into your research workflow, whether as a standalone tool or as a complement to a traditional life sciences database, is that you get contextual intelligence across the full market landscape — not just commercial data.

AlphaSense’s features include:

Premium External Market Intelligence

If Evaluate provides the quantitative foundation by delivering historical sales data, consensus sales forecasts, and structured commercial intelligence, AlphaSense serves as the contextual layer, surfacing insights across over 500 million unstructured documents to help teams interpret clinical and regulatory developments in real time. These documents include:

• Broker reports from top Wall Street firms that help healthcare leaders understand how the market is interpreting key clinical, regulatory, and competitive developments
• Earnings call transcripts and management commentary that reveal strategic priorities, commercial expectations, capital allocation decisions, and emerging risks directly from company leadership
• Expert call transcripts featuring KOLs, former regulators, and industry specialists that provide deeper interpretation of clinical data, trial design, regulatory dynamics, and standard-of-care shifts
• News and regulatory coverage to proactively monitor emerging risks and competitive moves

AlphaSense also provides cross-industry intelligence spanning biotech, healthcare services, diagnostics, medtech, and macroeconomic trends that surfaces external forces — from pricing pressure to policy shifts to capital markets dynamics — that materially impact life sciences strategy.

Integrated Internal Data

Users can also integrate and query their own internal content in AlphaSense alongside the premium external sources listed above. This can be particularly useful for users with access to both AlphaSense and Evaluate.

For example, users can easily ingest Evaluate’s curated reports directly into their private AlphaSense environment. From there, AlphaSense’s proprietary natural language processing and genAI features automatically index the Evaluate documents, while features like Generative Grids and Smart Summaries (see below) allow users to search across their proprietary Evaluate data and AlphaSense's public data simultaneously.

Data scientists and advanced BI teams can also feed Evaluate’s programmatic API and the AlphaSense API into a central Tableau or PowerBI dashboard, creating a unified visualization of clinical trial progress alongside shifting market sentiment.

Financial Data

AlphaSense provides access to the following crucial quantitative insights:

• Historical Financials & Estimates: Standardized statements and consensus data across 19,000+ public companies
• Sector-Specific KPIs: Detailed operating metrics sourced from institutional-grade Canalyst models
• Transaction Intelligence: Details on nearly 1 million M&A deals and 750,000 private funding rounds, enriched with AI-generated deal rationale and strategic context
• Dynamic Peer Sets: 125+ pre-built industry comparables with sector-specific metrics

AI Search and Summarization Technology

AlphaSense’s AI features help users extract crucial insights from each data source, enabling you to reduce research time, anticipate competitive moves earlier, and make faster, more confident strategic decisions.

Generative Search

With Generative Search, you can ask natural-language questions and source intelligence at scale from specific sources, including ClinicalTrials.gov, FDA, EMA, and PubMed — or from across our entire aggregated library of content. Generative Search will instantly return citable, verifiable answers, and you can dive deeper into each topic by asking follow-up questions or clicking into the source.

You can also take Generative Search on the go with our mobile app, giving you access to instant answers, wherever you work.

Generative Grid

Generative Grid applies multiple genAI prompts to many documents at the same time to quickly provide organized answers to research questions at scale, in an easy-to-read table format. Generative Grid pulls data from both premium external documents in the AlphaSense platform and users’ internal content. Users can leverage this tool to track clinical trials, compare competitors at a glance, parse through medical studies in seconds, track biopharma deal activity, or analyze merger proxy filings, among many other use cases.

Smart Summaries

Every earnings transcript in AlphaSense features an AI-generated Smart Summary, which creates a tearsheet of key takeaways, analyst Q&A, and the most critical topics discussed in each call. Life sciences professionals can use Smart Summaries to instantly extract key insights from competitors’ earnings transcripts.

Sentiment Analysis

Sentiment analysis, an NLP-based feature, parses content and identifies nuances in language such as tone and subjective meaning. It then uses color coding to help users identify instances of positive, negative, and neutral sentiment throughout the document.

Monitoring, Analysis, and Collaboration Tools

AlphaSense is designed to help users uncover insights faster with the following tools:

• Customizable dashboards create a centralized information hub for monitoring key companies and themes, while tailored alerts provide real-time updates.
• Powerful collaboration tools like Notebook and commenting features help teams manage and share insights more effectively.
• Table Tools allow you to move faster with spreadsheet-style visualizations directly from company filings, so you can chain together, edit, and optimize tables for analysis.
• Image Search allows you to discover insights buried in charts to quickly return data without reading through pages of documents.
• Snippet Explorer allows you to effortlessly assess any topic or theme and all its historical mentions in a single view.
• A mobile app that lets you track real-time alerts and run AI searches on the go, ensuring you never miss a critical insight.
• Automated Monitoring allows you to set up real-time alerts that send instant updates on any relevant market movements, news, emerging trends, and competitor activities. We also generate snapshots of companies and topics regularly that keep you ahead of the curve with actionable insights.

AlphaSense Pros:

• Extensive content database that spans key market perspectives, including broker research, expert calls, company documents, news, and regulatory sites
• Extensive quantitative insights and financial data workflow and analysis tools
• AI and genAI tools that users can apply to integrated internal content alongside platform content
• 4,500+ pre-built financial models that update automatically
• Live transcripts that allow users to view past, present, and future event transcripts in a calendar and view event transcripts in real time
• Automated and customizable real-time alerts
• All-in-one research platform
• User-friendly interface
• Internal note-taking, sharing, and collaboration features
• Support for APIs and integrations
• Supports enterprise-level organizations and teams
• A mobile app designed for on-the-go workflows, providing access to our full content library, generative search, and alerts
• Excellent customer support team, including 24/7 chat with product specialists, a Live Help button on the website, and regular live AlphaSense Education webinars

AlphaSense Cons:

• Visualization tools are limited at this time
• Collaboration tools are limited to users with AlphaSense licenses

Evaluate

Best for: Drug pipeline valuation, consensus sales forecasting, and risk-adjusted portfolio decision-making

Evaluate is the leading tool for valuation and forecasting in the pharmaceutical space and is considered the industry standard for consensus forecasts. If you need to build a business case for an acquisition or justify an R&D budget to a board of directors, Evaluate is the right tool. Evaluate is best for working with structured quantitative datasets, meaning a complementary platform is needed for additional context.

Evaluate includes the following key features:

Deep Commercial and Forecast Intelligence

Evaluate’s core strength lies in its standardized commercial performance data and consensus sales forecasts across the global pharmaceutical market. Built-in datasets include:

• Consensus sales forecasts aggregated from leading equity analysts
• Historical commercial performance data across products, companies, and therapy areas
• Linked pipeline-to-market views that connect assets to projected commercial outcomes
• Therapy area and indication-level market sizing
• Company-level benchmarking and revenue concentration analysis

With these datasets, teams can systematically compare commercial potential, prioritize assets, and assess competitive positioning using a consistent analytical framework.

However, Evaluate’s focus is primarily on structured and modeled datasets. It does not provide broad access to unstructured sources such as earnings transcripts, SEC filings, broker research, or expert interviews. As a result, it cannot surface the qualitative context needed to understand the strategic drivers, sentiment shifts, or market signals behind the numbers.

Specialized Modules and Analytical Workflows

Evaluate is designed with several key modules, each with a slightly different focus and set of use cases. These modules include flagship products such as Evaluate Pharma and Evaluate Omnium, as well as Evaluate Epi, Biomedtracker, Competitive Intelligence, and more.

The key workflows these models support include:

Market Sizing and Forecasting

With its suite of forecasting solutions, Evaluate offers an unmatched view into global pharma markets and enables you to develop informed forecasts on your key assets. Key modules in this use case include Evaluate Pharma, Evaluate Omnium, Evaluate Epi, and Pharma Forecasting.

Business Development and Licensing

Evaluate enables you to compare candidates based on commercial, clinical, and scientific criteria such as market novelty, potential revenue, competitive intensity, and partner suitability. Key modules in this use case include Evaluate Pharma, Evaluate Omnium, BioSciDB, and Biomedtracker.

Portfolio Optimization and Asset Strategy

Evaluate gives you the competitive edge you need to navigate the market’s complexities, optimize your pipeline, develop comprehensive scenario planning, and prioritize the right indications. Key modules in this use case include Evaluate Pharma, Biomedtracker, Datamononitor Healthcare, and Competitive Intelligence.

Competitive Intelligence

Evaluate helps you stay competitive by providing tracking, analysis, and strategic intelligence to support decision-making processes across drug development, manufacturing, and market competition. Key modules in this use case include Competitive Intelligence, Biomedtracker, Evaluate Epi, and Evaluate Pharma.

Consulting and Analytics

Evaluate’s custom analytics team helps you address unique commercial challenges. With access to extensive data assets and experience across therapy areas and modalities, the team partners with you to provide the answers you need to drive success. Key modules in this use case include Custom Analytics, Custom Model Build, and Pharma Forecasting Training.

AI Capabilities

Evaluate incorporates machine learning and predictive analytics to support forecasting, risk/return analysis, and decision modeling within pharma.

Specific capabilities include:

• Consensus aggregation and forecast tracking across multiple analyst models
• Machine learning-driven risk/return scoring for pipeline assets
• Standardized commercial comparables across therapy areas
• Scenario and analog-based modeling to stress-test assumptions
• Ranking and filtering tools for opportunity prioritization
• Intelligent alerts and dynamic analytical tools that help users monitor changes in forecast assumptions, pipeline risk, and competitive landscapes over time

While Evaluate’s AI enhances how forecasts are modeled and compared within structured datasets, it does not extend to analyzing or synthesizing the vast universe of unstructured market content that often shapes those forecasts. That’s where AlphaSense adds significant value by applying advanced AI and generative technology to millions of documents and surfacing crucial insights in real time.

Together, the platforms connect predictive commercial modeling with live market interpretation — allowing teams not only to stress-test assumptions, but to continuously validate them against evolving external signals.

Evaluate Pros:

• Strong consensus-forecasting and market-sizing capabilities
• Broad pipeline visibility that includes early-phase and private pipeline data
• Enables standardized cross-company portfolio comparisons
• Integrated within Norstella so users can use adjacent tools like Citeline for broader clinical and regulatory intelligence
• Incorporates AI and predictive analytics to support forecasting, risk/return analysis, and decision modeling in pharma

Evaluate Cons:

• Consensus forecasting is dependent on analyst coverage so can be inconsistent
• Primarily structured data with limited qualitative context
• Less clinical depth than R&D-focused platforms like Cortellis
• No generative AI or sentiment analysis
• No broker reports to help pharma leaders understand how the market is interpreting key clinical, regulatory, and competitive developments
• No earnings call or expert call transcripts that reveal strategic priorities, commercial expectations, capital allocation decisions, and emerging risks directly from company leadership
• No expert call transcripts featuring KOLs, former regulators, and industry specialists that provide deeper interpretation of clinical data, trial design, regulatory dynamics, and standard-of-care shifts

AlphaSense and Evaluate: Take Your Research to the Next Level

Evaluate and AlphaSense are not substitutes — they are strategic complements. Evaluate provides the structured commercial foundation life sciences teams rely on to assess drug sales forecasts, benchmark competitors, size markets, and prioritize pipeline investments. AlphaSense layers on the market narrative: how executives are framing guidance, how analysts are adjusting expectations, how experts are interpreting clinical data, and where competitive sentiment is shifting in real time.

In an industry where a forecast revision, regulatory signal, or competitive announcement can materially alter valuation and strategy, structured projections alone are not enough — and neither is qualitative insight without a quantitative backbone. The most sophisticated life sciences organizations recognize that confident decision-making requires both.

If your team already relies on Evaluate for commercial forecasting and portfolio analytics, AlphaSense can amplify its value by connecting those projections to the broader market conversation so that you get a much more complete market view.

In addition, AlphaSense’s advanced AI capabilities enable teams to further interrogate and contextualize Evaluate data — quickly identifying supporting commentary, conflicting viewpoints, and emerging developments that may impact forecast assumptions. The result is faster insight generation, fewer blind spots, and more proactive strategic decisions.

Start a free trial of AlphaSense to see how AI-powered market intelligence can strengthen your existing research workflows and help your team stay ahead of shifting market dynamics.